X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Dr. Reddy’s: Ground realities - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jul 27, 2002

    Dr. Reddy’s: Ground realities

    Early during the week, Dr. Reddy’s stock fell more than 16% in the intra day movement. This was in reaction to the suspension of clinical trials for its anti-diabetic molecule licensed to Novo Nordisk. This came as a major setback for the company. DRF-2725, the dual acting insulin sensitiser termed as ‘Ragaglitazar’ was amongst the major catalyst for the company’s research efforts.

    The life cycle of Ragaglitazar:
    Ragaglitazar was one of the two anti-diabetic molecules, which were out-licensed to Novo Nordisk in March 1997. Subsequently, Novartis Pharma AG, entered into agreement for commercialization with Novo Nordisk, only to withdraw the tie-up later. The molecule entered into the Phase III trials in November last year creating huge hopes for the company. Had the molecule entered the commercial stage, it would have been the first to reach the market from a new generation dual acting sensitisers globally. It may be mentioned here that Glaxo faced a similar set back in October last year, when its insulin sensitiser was withdrawn from Phase III trials. There are several other drug majors researching on insulin sensitisers including Merck and AstraZenca molecules who are in late Phase II trials.

    Best & worst case scenarios:
    The side effects of the drug have been observed only on rodent’s species currently and it could be of no relevance to humans. However, for patients’ safety reasons, Novo Nordisk decided to take precautionary approach and has suspended the ongoing clinical trials. Currently, all clinical trials involving Ragaglitazar have been stopped and all planned new clinical trials have been postponed as the side effects on rodent species are being investigated further.

    New trials can resume if the data is found to have no human significance. However, the Phase III filings and hence US$ 10 m payment expected to be received by Dr. Reddy’s would be delayed by at least 24 months. In the worst-case scenario, if the data of the studies is found to have human significance, Ragaglitazar compound would be dropped and there would be no further royalty payments for the company.

    Ragaglitazar or not, the long-term business prospects of Dr. Reddy’s remain intact. The research spend of the company has been on the rise in the last few years and is expected to continue its momentum going forward. While such disappointments are not uncommon in the international pharma market, it was first of its kind for Indian companies. It is worth reiterating over here that probability of success in pharma research is only one out of several thousand molecules. The incident has atleast brought investors face to face with the risk profile of a research based pharma company.

    We had not factored in any revenues (either royalty or milestone) from Ragaglitazar due to uncertainty and hence there is no change in our forward EPS estimates for FY03. It may be recalled that one-time revenues from high margin generic exports of fluoxetine fuelled FY02 financials and hence EPS is slated to register a slide in the current year.

    Rs m FY02 FY03E
    Net Sales 15,211 15,055
    Operating Profits 4,798 3,944
    Operating Margins % 31.5% 26.2%
    Profit after tax 4,597 3,213
    EPS (Rs) 60.1 42.0

    Another major catalyst for Dr. Reddy’s is the revenue potential from Para IV product filings, which again is highly uncertain revenue stream. Without any exception, these filings are prone to heavy litigation and the final outcome of this is again difficult to forecast. But on the other hand, there is a huge upside potential if successful.

    A case in point here is two Para IV ANDA filings of Prozac (fluoxetine) and Prilosec (Omeprazole). The final approval for generic version of the antidepressant Prozac was massive revenue grosser for the company. For FY02, this single product contributed US$ 67 m (more than 21% of the company’s total turnover), with operating margins in the range of 75-80%. Profits were more than US$ 50 m from this single product as against a total net profit of US$ 30 m in FY01.

    On the other hand, the company’s another Para IV filing for Omeprazole, turned out to be a major disappointment. Following withdrawal of its tentative Omeprazole approval, the company lost out on a big opportunity at least initially.

    Dr. Reddy’s has a host of big potential products like Olanzapine, Ondansetron, Clopidogrel and Terbinafine HCl in its US generics Para IV filings pipeline, which could generate considerable revenues for the company going forward. An indication of a probable launch of these products is given in the table alongside along with possible revenues in the first year of launch. These are products with tremendous potential but with higher risk and uncertainty. As can be seen from the table below, the company has a fairly good product line up for the next 5 years.

    Dr. Reddy’s: Generics Coffer
    Product Expected Launch
    Year
    Therapeutic segment Est. Sales in year
    of launch (US$ m)
    Omeprazole FY04 Anti-ulcerants 23
    Ciprofloxacin HCL FY05 Anti-infective 3
    Olanzapine FY05 Anti-depressant 15
    Ondansetron FY05 Anti-emetic 64
    Clopidogrel Bisulfate FY06 Cardiovascular 50
    Amlodipine Maleate FY06 Cardiovascular 75
    Terbanifine HCL Tablets FY07 Anti-infective NA

    On a conservative side, we have included revenues only with reasonable certainty. The company pursues such opportunities on a continuous basis and the list is likely to expand. At the current market price of Rs 833, the stock trades at a P/E of 20.5x its FY03E earnings. Without any revenue surprises, valuations look adequate and thus, the stock is likely to remain range bound for a while. However, the stock could witness a re-rating as and when certainty on any news flows on the success of Para IV filing surfaces.

     

     

    Equitymaster requests your view! Post a comment on "Dr. Reddy’s: Ground realities". Click here!

      
     

    More Views on News

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

    Sep 12, 2016

    Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    DR. REDDYS LAB SHARE PRICE


    Aug 17, 2017 (Close)

    TRACK DR. REDDYS LAB

    • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    DR. REDDYS LAB - TTK HEALTHCARE COMPARISON

    Compare Company With Charts

    COMPARE DR. REDDYS LAB WITH

    MARKET STATS